Scholarlink

Purpose <p>To evaluate the prelaminary clinical effects of subconjunctival injectable platelet-rich fibrin (i-PRF) in patients with severe dry eye disease (DED).</p> Methods <p>This study included two groups: an i-PRF group consisting of 28 eyes treated with subconjunctival i-PRF injection and a control group of 32 eyes. The ocular surface disease index (OSDI-12), tear break-up time (TBUT), corneal fluorescein staining (CFS), tear meniscus height (TMH), and tear meniscus area (TMA) were assessed at baseline and during follow-up. Changes in clinical parameters were compared between the groups.</p> Results <p>Baseline demographic characteristics and dry eye parameters were comparable between the groups (all <i>p</i> &gt; 0.05). After three injections, the i-PRF group showed a significantly greater reduction in OSDI-12 and CFS scores, as well as a significant increase in TBUT, compared with the control group. Tear meniscus parameters also improved in the i-PRF group, with TMH increasing from 145.9 ± 28.5 (143.0) to 254.3 ± 35.3 (258.5) µm and TMA from 0.015 ± 0.004 (0.016) to 0.043 ± 0.005(0.043) mm².</p> Conclusion <p>Subconjunctival i-PRF injection was associated with improvements in both subjective symptoms and objective ocular surface parameters in patients with severe DED. These preliminary results suggest that i-PRF may be a promising adjunctive treatment option for patients refractory to conventional therapies. Further prospective controlled studies with longer follow-up are needed to confirm its efficacy and durability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Subconjunctival injectable platelet-rich fibrin for severe dry eye disease: Preliminary clinical results

  • 期刊论文

  • 发表日期：

    2026年4月24日

查看全文
  • Huri Sabur,
  • Ayse Nur Coban,
  • Nese Arslan,
  • Alperen Bahar

摘要

Purpose

To evaluate the prelaminary clinical effects of subconjunctival injectable platelet-rich fibrin (i-PRF) in patients with severe dry eye disease (DED).

Methods

This study included two groups: an i-PRF group consisting of 28 eyes treated with subconjunctival i-PRF injection and a control group of 32 eyes. The ocular surface disease index (OSDI-12), tear break-up time (TBUT), corneal fluorescein staining (CFS), tear meniscus height (TMH), and tear meniscus area (TMA) were assessed at baseline and during follow-up. Changes in clinical parameters were compared between the groups.

Results

Baseline demographic characteristics and dry eye parameters were comparable between the groups (all p > 0.05). After three injections, the i-PRF group showed a significantly greater reduction in OSDI-12 and CFS scores, as well as a significant increase in TBUT, compared with the control group. Tear meniscus parameters also improved in the i-PRF group, with TMH increasing from 145.9 ± 28.5 (143.0) to 254.3 ± 35.3 (258.5) µm and TMA from 0.015 ± 0.004 (0.016) to 0.043 ± 0.005(0.043) mm².

Conclusion

Subconjunctival i-PRF injection was associated with improvements in both subjective symptoms and objective ocular surface parameters in patients with severe DED. These preliminary results suggest that i-PRF may be a promising adjunctive treatment option for patients refractory to conventional therapies. Further prospective controlled studies with longer follow-up are needed to confirm its efficacy and durability.